MedTrace Logo

Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers

NCT01284621 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2014-07-22

Study results available
· View outcomes & findings →

Summary

Primary objective:To investigate if BI 10773 affects the pharmacokinetics of ramipril and if ramipril affects the pharmacokinetics of BI 10773.

Conditions

  • Healthy

Interventions

DRUG

BI 10773

medium dose, oral administration

DRUG

Ramipril

Medium dose oral administration on day 2-5

DRUG

BI 10773

medium dose oral administration

DRUG

Ramipril

Low dose oral administration on day 1

DRUG

Ramipril

Low dose oral administration on day 1

DRUG

Ramipril

Medium dose oral administration on day 2-5

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01284621 on ClinicalTrials.gov